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Short Communication
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The potential role of Interferon (IFN) in the
treatment of malignant disease is currently being
evaluated. Some central nervous system (CNS)
toxicity, usually manifested by drowsiness or
confusion has been recorded with all IFN
preparations, almost regardless of the dose and
schedule (Priestman 1980, Scott et al., 1981) and it
was shown to be the major dose-limiting toxicity
when high doses of IFN derived from Namalwa
lymphoblastoid cells (HuIFN-aN) were
administered by continuous i.v. infusion (Rohatiner
et al., 1982). It was therefore decided to undertake a
formal study of the CNS side effects of HuIFN-axN
and gene-cloned HuIFN-a2, given at the dose
selected on the basis of Phase I Studies for the
treatment of myelogenous leukaemia. The results of
this study comprising clinical examination, serial
electroencephalography (EEG), investigation of eye
movements, biochemical tests of metabolic function
and serum and cerebrospinal fluid IFN levels are
presented below.
Eleven patients were investigated, 8 prospectively
(4 acute myelogenous leukaemia (AML), 2 chronic
myeloid leukaemia (CML), 1 chronic lymphocytic
leukaemia (CLL) and 1 follicular lymphoma) and 3
retrospectively (AML). The latter are included
because of the inevitably limited data concerning
cerebrospinal fluid IFN concentrations.
Seven patients received HuIFN-axN (Wellcome
Research Laboratories, specific activity:
2.13 x 108 u.mg- protein). Four patients were
treated with gene-cloned HuIFN-CX2 (Schering
Plough, specific activity: >2 x 108u.mg- protein).
All patients received 100x 106u.m-2 per day
administered by continuous i.v. infusion for 7 days,
with the exception of one patient who received a
second cycle at half the dose and another (in the
Phase I study) who received 200 x 106 u.m-2 per day
for 5 days.
Clinical toxicity was assessed by daily
observation of the general demeanour of the patient
and direct questioning aimed at eliciting any
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intellectual impairment. Formal psychometric
testing was not undertaken.
Serial EEGs (43 in total) were performed prior to,
during and up to one month after completion of
therapy. EEG abnormalities fell into 5 categories
(vide infra). Each of these was rated visually on a 3-
5 point scale independently of clinical information
and the scores were summed, a normal EEG
scoring 0, a total score of 15 denoting maximum
abnormality.
Blood urea and electrolytes, serum calcium,
phosphate and tests of liver function were monitored
daily. Serum was collected daily and in 5 patients
cerebrospinal fluid (CSF) was obtained on the
second day of therapy, thrombocytopenia
precluding this investigation in the remainder.
Serum and CSF samples were stored at -20°C for
subsequent estimation of the IFN concentrations.
IFN concentrations were measured by reduction
of viral RNA synthesis in WISH cells (Flow
Laboratories, Irvine, Scotland) challenged with
Semliki forest virus.
All patients became pyrexial and complained of
anorexia, fatigue and general malaise, describing
symptoms similar to those of influenza. Seven of the
11 patients became drowsy 24-72h after
commencing IFN therapy. Although the patients
appeared intellectually intact, further questioning
revealed them to be withdrawn, slow to answer
questions and totally disinterested in their
surroundings, sleeping for most of the day. (One
patient developed severe bronchopneumonia on
Day 3 and some of his symptoms may have been
attributable to hypoxia.) Three of the 7 patients
became disorientated in time and place in spite of
familiarity with the ward; one patient experienced
visual hallucinations 1 week after completing the
IFN infusion (HuIFN-a2) and another complained
of feeling drowsy, lethargic and somewhat "distant"
though he appeared alert and fully orientated.
Three patients had no clinical evidence of CNS
disturbance. No focal neurological signs were
elicited.
Pretreatment EEGs were normal except for
minor changes in 2 patients. During the course of
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the IFN infusion a characteristic pattern of severe,
reversible abnormality evolved in all patients
studied regardless of whether clinical evidence of
CNS toxicity was present (Figure). The following
changes were observed sequentially: (1) slowing of
the dominant alpha rhythm with (2), gradual loss of
attenuation on eye opening and (3), the appearance
of diffuse slow waves (theta then delta). Initially
these could be blocked by eye opening or auditory
stimuli and so may have reflected drowsiness.
However, (4), they gradually became less responsive
to external stimulae until eventually (5) frontally-
accentuated intermittent delta bursts became very
prominent. Abnormality scores derived from the
summed scores of the 5 rating scales reached a peak
on days 6-11 of the IFN infusion returning towards
normal by 2-3 weeks. Lambda waves also showed a
parallel, transient increase of up to 100%, in
number, voltage and duration.
In Patient no. 8, eye movements and visual
evoked potentials were also investigated. Smooth
pursuit velocity of eye movements, saccadic reaction
times and pattern evoked potential latencies were at
the extreme of the normal range: they returned
towards mean normal values 3 weeks after
completing Hu IFN-CX2 therapy.
Peak serum IFN levels ranged from 268-
2,500u.ml- I (Table). A CSF level of 50u.m-l was
recorded in one patient at a time when the serum
level was >1000u.ml-1. In the other 4 patients in
whom it was possible to perform a lumbar
puncture, IFN concentrations were consistently
<lOu.m- 1.
Evidence of transient hepatic dysfunction was
observed in all patients, with marked rises in
alkaline phosphatase and transaminases (Table).
Patients 2 and 10, receiving 100 and
200 x 106u.m-2 per day respectively became
hypocalcaemic. However, correction of the serum
calcium did not alter the degree of drowsiness or
confusion. No other electrolyte disturbances were
observed though patient 10 also developed signs
of renal impairment.
Eight patients receiving IFN derived from 2
different sources were studied prospectively in order
to evaluate CNS toxicity at a dose of
100 x 106 u.m2 per day administered by
continuous i.v. infusion. Serum and CSF levels were
obtained in a further 3 patients. Eight of the 11
patients developed clinical evidence of CNS
disturbance during the course of the IFN infusion.
This confirms the Phase I experience with HuIFN-
aN when drowsiness and disorientation were
observed in patients receiving 100 and
200 x 106u.m2 per day (Rohatiner et al., 1982).
The EEG became markedly abnormal with
changes suggestive of an encephalopathy, even in
patients who had no clinical evidence of CNS
toxicity. The degree of abnormality did not reflect
the patients' clinical state and did not correlate with
serum IFN concentrations. The EEG changes
described are similar to those observed by Obrecht
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Figure 1 Typical EEG appearance at the height of the toxic state in patient no. 1 (left) with subsequent
recovery (right).
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Table I Clinical toxicity, serum and CSF IFN concentrations, biochemical parameters and EEG peak scores in
patients receiving 100 x 106 u.m-2 per day ofHuIFN-axN or HuIFN-cx2
Peak serum CSF IFN EEG
Patient CNS IFN level level Urea + Liverfunction Ca+ Peak
no. Disturbance (u.ml- ') (u.ml- 1) Electrolytes tests* P04 Score
1 + + + 880 ND N tAlk.phosph. N 13
TTransaminases
2 + + + ND ND N TAlk.phosph. tCa 11
TTransaminases
3 none 765 <10 N TAlk.phosph. N 9
tTransaminases
4 + 750 ND N TAlk.phosph. N 3
tTransimanases
5 none 268 ND N TAlk.phosph. N 13
tTransaminases
6 + + 432 <10 N tAlk.phosph. N 14
tTransaminases
7 + + + 848 ND N TAlk.phosph. N 10
tTransaminases
8 none 1072 ND N tAlk.phosph. N 10
TTransaminases
9 + + 1000 50 N TAlk.phosph. N ND
TTransaminases
10 + + + 2500 <10 turea TAlk.phosph. iCa ND
Tcreatinine Tlransaminases
TAlk.phosph.
11l + + + 848 <10 N tTransaminases N ND
ND=not done
N=within normal limits
* =transient rises in hepatic enzymes.
et al. (1979) in one third of patients with toxic
confusional states of both intra- and extra-cranial
origin. Slowing of the dominant alpha rhythm has
also been reported in patients receiving
conventional cytotoxic agents (Schaffler et al., 1982).
The clinical findings and the EEG changes were
the same with both types of IFN and could not be
attributed to biochemical changes though transient
abnormalities of hepatic enzymes were observed. In
3 patients who had 2 cycles of IFN, similar EEG
changes were observed on each occasion.
IFN was present in the CSF in only 1 patient.
Low levels have previously been reported in
patients receiving IFN systemically (Priestman
1980, Salazar et al., 1982). The mechanism
accounting for these CNS effects is unclear though
IFN has been shown to enhance neuronal
excitability (Calvet & Gresser 1979) and enhanced
levels of p67K Kinase, an IFN-induced enzyme,
have been demonstrated in the brain of mice treated
with IFN (Krust et al., 1982). Mattson et al. (1982)
noted very similar EEG changes in patients with
oat-cell lung cancer receiving high doses of
leucocyte HuIFN-azN. Whether these changes are
dose dependent remains to be established.
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in the study and are pleased to acknowledge the
contribution of the medical and nursing staff on Dalziel
and Annie Zunz wards. We are most grateful to the
technical staff of the Departments of Medical Oncology
and Haematology and the ICRF Interferon Laboratory.
Our thanks to Sara Godleman for preparing the
manuscript.
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